glp 1 gut hormone GLP-1 Receptor Agonist Services for Type 2 Diabetes and Obesity Drug Development The Ultimate Guide to GLP-1:

The benefit of GLP-1 RAs exceeded the harms for weight loss in the first 2 years of treatment, yet the net benefit was dependent on individual treatment goals (10% or 5% weight loss) and willingness to accept harms in pursuit of weight loss

Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs

Reactions persisting beyond 5-7 days without improvement warrant medical evaluation

[1] The most frequently reported adverse effects in clinical trials were gastrointestinal in nature, including nausea (12-22%), diarrhea (12-16%), vomiting (6-10%), and constipation (6-7%), with rates varying by dose